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Abstract
Background: Although remote monitoring (RM) has proven its added value in various health care domains, little is known
about the remote follow-up of pregnant women diagnosed with a gestational hypertensive disorders (GHD).
Objective: The aim of this study was to evaluate the added value of a remote follow-up program for pregnant women diagnosed
with GHD.
Methods: A 1-year retrospective study was performed in the outpatient clinic of a 2nd level prenatal center where pregnant
women with GHD received RM or conventional care (CC). Primary study endpoints include number of prenatal visits and
admissions to the prenatal observation ward. Secondary outcomes include gestational outcome, mode of delivery, neonatal
outcome, and admission to neonatal intensive care (NIC). Differences in continuous and categorical variables in maternal
demographics and characteristics were tested using Unpaired Student’s two sampled t test or Mann-Whitney U test and the
chi-square test. Both a univariate and multivariate analysis were performed for analyzing prenatal follow-up and gestational
outcomes. All statistical analyses were done at nominal level, Cronbach alpha=.05.
Results: Of the 166 patients diagnosed with GHD, 53 received RM and 113 CC. After excluding 5 patients in the RM group
and 15 in the CC group because of the missing data, 48 patients in RM group and 98 in CC group were taken into final analysis.
The RM group had more women diagnosed with gestational hypertension, but less with preeclampsia when compared with CC
(81.25% vs 42.86% and 14.58% vs 43.87%). Compared with CC, univariate analysis in RM showed less induction, more
spontaneous labors, and less maternal and neonatal hospitalizations (48.98% vs 25.00%; 31.63% vs 60.42%; 74.49% vs 56.25%;
and 27.55% vs 10.42%). This was also true in multivariate analysis, except for hospitalizations.
Conclusions: An RM follow-up of women with GHD is a promising tool in the prenatal care. It opens the perspectives to reverse
the current evolution of antenatal interventions leading to more interventions and as such to ever increasing medicalized antenatal
care.
(JMIR Mhealth Uhealth 2017;5(3):e25)   doi:10.2196/mhealth.6552
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Introduction
Background
Gestational hypertensive disorders (GHD) remain one of the
most significant and intriguing unsolved problems in obstetrics
[1,2]. It is estimated that 5-10% of pregnancies are complicated
by this disease, and it is one of the major causes of maternal
and fetal morbidity and mortality [1,3,4]. GHD is defined as
new onset hypertension (diastolic blood pressure ≥90 mmHg
and systolic blood pressure ≥140 mmHg), with or without
proteinuria (≥300 mg in 24-h urine collection) at or after 20
weeks of gestation [1]. The most common management for
GHD in Belgium is an admission to the prenatal observation
unit for diagnostic and therapeutic follow-up before induction
of labor or discharge at home. In severe cases, premature birth
is indicated [1].
As part of the Hasselt University and the Limburg Clinical
Research Program (LCRP), Ziekenhuis Oost-Limburg (Genk,
Belgium) initiated in January 2015 a remote monitoring (RM)
program for women with or at risk for GHD. RM is an
alternative approach in medical management (dating back to
the early 1990s) facilitating patients’ management at home [5].
It is defined as the use of telecommunication technologies to
assist the transmission of medical information and services
between health care providers and patients. The use of this
2-way telecommunication technology, using multimedia and
computer networks, to assist medical management is a growing
trend internationally [6].
In this paper, we report our first clinical results of RM in GHD,
obtained retrospectively during the year of technical installation
of remote communication between hospital doctors or midwives
and pregnant women at home.
Related Work
RM has already shown benefits in Cardiology and Pneumology
[7,8]. In the prenatal care, RM has also shown an added value
to improve maternal and neonatal outcomes. Various studies
reported a reduction in unscheduled patient visits, low neonatal
birth weight, and admissions to neonatal intensive care (NIC)
for pregnant women who received RM compared with pregnant
women who did not receive these devices. Additionally, RM
can contribute to significant reductions in health care costs. RM
was also demonstrated to prolong gestational age and to improve
feelings of self-efficacy, maternal satisfaction, and gestational
age at delivery when compared with a control group which did
not received RM [9-16]. Unfortunately, some of the previous
mentioned studies are dating back to 1995 and no more recent
work is available. This is in contradiction with the rapid
technological advancements that have been seen in the last
decade. Further, no studies are published about the added value
of RM in pregnant women with GHD. To our knowledge, this
is the first publication about a prenatal follow-up program for
pregnant women with GHD to date.
Methods
Subjects
All women diagnosed with GHD who delivered at the outpatient
prenatal clinic of Ziekenhuis Oost-Limburg (Genk, Belgium)
during 2015 were included. Women received RM on demand
of the responsible obstetrician before admission or after
discharge from the prenatal observation ward. The criteria to
initiate RM were GHD at gestational age ≥20 weeks where an
intensive follow-up until delivery was desirable. Women without
a mobile phone, a gestational age less than 20 weeks, a fetus
with congenital malformations, and women who refused
informed consent were excluded and received conventional care
(CC).
Between January 1, 2015 and December 31, 2015, there were
2058 women who had prenatal care and delivery at Ziekenhuis
Oost-Limburg. It was found that 166 women were diagnosed
with GHD, 53 of them received CC added with RM. The
remaining 113 pregnant women with GHD did not receive RM
but only CC.
Interventions in the Remote Monitoring Group
Women consenting for RM received obstetric surveillance by
a Withings Wireless Blood Pressure Monitor, Withings Smart
Body Analyzer, and a Withings Pulse O² (Withings,
Issy-les-Moulineux, France). Pregnant women participating in
the prenatal remote follow-up program were asked to perform
one blood pressure measurement in the morning and one in the
evening, one weight measurement a day, and wear an activity
tracker day and night until delivery or hospital admission (see
Figure 1).
The data from the monitor devices were transmitted to a
Web-based dashboard developed by the Mobile Health Unit of
the University of Hasselt. Predetermined alarm signals were
set; one midwife performed remote follow-up of all transformed
data at the dashboard. She had to discriminate normal and alarm
signals of systolic blood pressure >140 mmHg, diastolic blood
pressure >90 mmHg, or weight gain >1 kg/day. Alarm events
were communicated with the obstetrician in charge to discuss
management options before contacting and instructing patients
at home. Type of interventions were (1) expectant management,
(2) ambulatory blood sampling and 24-h urine collection at
home, (3) adjustment of the antihypertensive therapy or physical
activity, (4) admission to the antenatal ward, and (5) induction
of labor. Therapeutic interventions were according to local
management.
The hospital’s Medical Ethics Committee approved the study.
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Figure 1. The equipment used in the remote monitoring group.
Maternal Demographics
Maternal demographics and characteristics of the patients in the
RM group were collected at study entry. In the CC group, these
data were obtained by manual search through the electronic
medical records.
Primary Outcome: Prenatal Follow-Up
Total numbers of prenatal consultations were collected from 10
weeks of gestation onwards: ultrasound scans,
cardiotocographics (CTG), admission to the prenatal ward, total
days of hospitalization, and the number of admissions until
delivery. These data were retrospectively collected from the
electronic medical records after the delivery of the women in
both the RM and CC group. These data were checked with the
hospital administration and billing records.
Secondary Outcomes: Delivery Outcomes
Maternal parameters collected at birth were gestational age at
delivery and mode of delivery. Neonatal outcomes collected
were birth weight, birth weight percent, length, Apgar at 1′ and
5′, and number of admissions to NIC.
Statistical Analysis
Differences in continuous and categorical variables in maternal
demographics and characteristics were tested using Unpaired
Student’s two sampled t test or Mann-Whitney U test and the
chi-square test. Both univariate and multivariate analyses were
performed for analyzing prenatal follow-up and gestational
outcomes. Beta coefficients and 95% CI were calculated for
multivariate analysis. All statistical analyses are done at nominal
level, Cronbach alpha=.05. Statistical analysis was performed
with Statistical Package for Social Sciences release 22.0 (IBM
SPSS Inc).
Results
Participant Demographics
Of the 2058 deliveries in Ziekenhuis Oost-Limburg in 2015,
18.06% (166/2058) were diagnosed with GHD and had both
prenatal care and birth in the same hospital. A total of 31.92%
(53/166) (31.92%) of the GHD pregnancies had RM. Of these,
3.01% (5/53) were excluded from analysis because of missing
data (n=4) and fetal loss (n=1). In total, 28.92% (48/166) RM
women were eligible for analysis. The other 68.08% (133/166)
GHD pregnancies had CC. Of these, 9.04% (15/133) women
were excluded because of missing data, leaving 59.04% (98/166)
eligible for analysis. Figure 2 shows the study population in a
flowchart.
Table 1 shows the maternal demographics and characteristics
of the women diagnosed with GHD. In CC, there were more
primigravidas and smokers than in RM: 66.32% (65/98) versus
41.66% (20/48) and 10.20% (10/98) versus 0% (0/48),
respectively.
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Table 1. Maternal demographics and characteristics.
Statistical significance
(2-tailed),
P value
CCb group
(n=98)
RMa group
(n=48)
Variable
.7331.94 (4.77)31.69 (4.25)Maternal age in years, mean (SD)
.1176.80 (19.74)72.00 (17.99)Pre pregnancy weight (kg), mean (SD)
.38167.08 (6.86)166.00 (6.94)Height (cm), mean (SD)
.3227.08 (6.92)25.54 (5.58)BMI (kg/m²), mean (SD)
.00565 (66.32)20 (41.66)Primigravidity, n (%)
Concomitant diseases, n (%)
.481 (1.02)0 (0)Cardiovascular disorders
.611 (1.02)1 (2.08)Blood coagulation disorder
.815 (5.10)2 (4.16)Endocrine disorders
.992 (2.04)1 (2.08)Immunological disorders
.0210 (10.20)0 (0)Smoking, n (%)
.6611.21 ( 7.60)10.10 ( 5.36)GAc first visit in weeks, mean (SD)
aRM: remote monitoring.
bCC: conventional care.
cGA: gestational age.
Figure 2. The study population.
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Prenatal Follow-Up: Comparison Between RM and
CC
Data on prenatal follow-up balance are shown in Table 2. The
number of prenatal hospital admissions and admissions until
delivery were lower in RM than in CC when a univariate
analysis is performed: 56.25% (27/48) versus 74.49% (73/98),
and 27.08% (13/48) versus 62.24% (61/97). This was not
significant in multivariate analysis. For both uni- and
multivariate analysis was the prevalence of gestational
hypertension higher in RM than in CC (81.25% vs 42.86% and
beta=6.62), but the prevalence of preeclampsia was lower
(14.85% vs 43.87% and beta=.24).
Table 2. Prenatal follow-up.
Multivariate analysisUnivariate analysisVariable
P value95% CIc for betaRM versus no RM
(beta)
P valueCCb group
(n=98)
RMa group
(n=48)
.54−1.74 to 9.14−.56.908.86
(3.51)
8.77
(4.12)
Total number of prenatal visits, mean (SD)
.48−1.12 to 0.53−.08.461.89
(1.70)
2.23
(2.05)
CTG’s, mean (SD)
.48−0.56 to 1.19.07.083.67
(2.12)
3.95
(2.00)
Echo’s, mean (SD)
.090.18-1.45.46.0373 (74.49)27 (56.25)Prenatal admission, n (%)
.32−1.62 to 4.81.10.574.73
(5.69)
5.74
(8.98)
Days hospitalized, mean (SD)
.110.12-1.22.38<.00161 (62.24)13 (27.08)Prenatal admission until delivery, n (%)
Gestational outcome, n (%)
.119 (9.18)1 (2.08)Essential hypertension
<.0012.40-18.276.62<.00142 (42.86)39 (81.25)Gestational hypertension
.010.08-0.710.24<.00143 (43.87)7 (14.58)Preeclampsia
.534 (4.08)1 (2.08)HELLPc
aRM: remote monitoring.
bCC: conventional care.
cHELLP: hemolysis elevated liver enzymes and low platelets.
In order to investigate the influence of the maternal
demographics and characteristics on the prenatal follow-up, a
multiple linear regression analysis and a multivariate logistic
regression analysis is performed. A detailed overview of these
data is proved in Multimedia Appendix 1.
Delivery Outcomes: Comparison Between RM and CC
Delivery outcomes are shown in Table 3. For both uni- and
multivariate analyses, in the RM group, the number of
spontaneous start of the birth process was higher compared with
CC group: 60.24% (29/48) versus 31.63% (31/98) and
beta=3.25. Also, the number of inductions was lower in RM
group compared with CC group: 25.00% (12/48) versus 48.98%
(48/98) and beta=.36. Neonates in RM group did have a shorter
length compared with the CC group when performed a
multivariate analysis (beta=.23). Finally, neonates in the RM
group, compared with CC group, were less likely to be admitted
to the NIC department when performed a univariate analyses
(10.42%, 5/48 vs 27.55%, 27/98) but not in multivariate analyses
(beta=.34). Despite the significant differences in the start of the
birth process, there are no differences in the mode of delivery
between the two groups.
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Table 3. Delivery outcomes.
Multivariate analysisUnivariate analysisVariable
P value95% CI
for beta
RM versus no RM
(beta)
P valueCCb group
(n=98)
RMa group
(n=48)
.85−1.29 to 0.06−.21.9437.20
(3.20)
37.49
(2.52)
GAc delivery in weeks, mean (SD)
Start birth process, n (%)
.0011.36 to 7.783.25.00131 (31.63)29 (60.42)Spontaneous
.030.14 to 0.89.36.00648 (48.98)12 (25.00)Induction
.510.21 to 2.18.67.4819 (19.39)7 (14.54)Primary cesarean section
Mode of delivery, n (%)
.900.44 to 2.541.06.3858 (59.18)32 (66.67)Vaginal
.300.47 to 11.642.34.978 (8.16)4 (8.33)Instrumental
.510.21 to 2.18.67.4819 (19.39)7 (14.54)Primary cesarean section
.330.11 to 2.10.49.6313 (13.27)5 (10.42)Secondary cesarean section
.29−162.71 to 535.33.11.362953.09
(874.80)
3058.54
(692.60)
Birth weight in g, mean (SD)
.050.02 to 3.45.23.0748.33
(3.52)
49.53
(2.85)
Length in cm
.43−0.38 to 0.88.08.867.91
(1.63)
8.11
(1.20)
Apgar 1′, mean (SD)
.59−0.37 to 0.65.06>.999.03
(1.27)
9.13
(0.80)
Apgar 5′, mean (SD)
.080.10 to 1.14.34.0227 (27.55)5 (10.42)Admission NICd, n (%)
aRM: remote monitoring.
bCC: conventional care.
cGA: gestational age.
dNIC: neonatal intensive care.
In order to investigate the influence of the maternal
demographics and characteristics on the delivery outcomes, a
multiple linear regression analysis and multivariate logistic
regression analysis is performed. A detailed overview of these
data is proved in Multimedia Appendix 2.
Discussion
Principal Findings
We sought to determine whether RM was an added value to
facilitate the prenatal follow-up and to improve the delivery
outcomes in patients diagnosed with GHD. To our knowledge,
this is the first publication about a prenatal follow-up program
for pregnant women with GHD.
The findings show us a reduced appearance of preeclampsia,
but an increased appearance of gestational hypertension in the
group of women who received a prenatal RM program when
compared with women who received CC. Women in the RM
group, when compared with CC group, had a lower number of
prenatal hospitalizations, prenatal hospitalizations until delivery,
and their neonates were less likely to be admitted to the NIC
department in univariate but not in multivariate analysis. In both
analysis, spontaneous deliveries were more likely and inductions
less likely to occur in the RM group when compared with CC
group.
Strengths and Limitations
Despite the potential benefits, the use of RM in obstetrical care
is still very limited and is not integrated into healthcare systems.
The Commission of the European Communities has, in 2012,
written an eHealth Action Plan [17] in which they foster a spirit
of innovation in eHealth in Europe as the way forward to ensure
better health. Our study is one of the first studies in the
obstetrical care for women at risk for GHD which meets this
requirement. Additionally, one of the strengths of this study is
the fact that all patients had antenatal care and delivery in the
same hospital with electronic medical records in line with
administration files. Also, all patients had antenatal care
according to uniform local management protocols. Finally, the
percentage of missing data for RM group and CC group is 3.01%
and 9.04% respectively, which is a low value.
Our study has three main limitations. First, the data collection
was done retrospectively so selection bias cannot be excluded.
Second, in CC group, there were more primigravida and women
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who smoked during their pregnancy when compared with RM
group. Although, our multivariate analysis did not show any
influence of these parameters on our principal findings,
nulliparous women are known to have a higher risk for the
development of preeclampsia superimposed on chronic
hypertension [1,13] and smoking during pregnancy carries
adverse outcomes; however, a reduced risk of developing GHD
in women who smoke is shown by many studies [1,3]. The last
limitation is the interference from family doctors or community
midwives which cannot be excluded.
Comparisons With Previous Trials
To our knowledge, this is the first publication about a prenatal
follow-up program for pregnant women with GHD to date.
There are a few publications about a RM program during
prenatal follow-up in the management for pregnant women at
risk for preterm labor or with the diagnosis of gestational
diabetes mellitus. When looking at their maternal outcomes, the
results of these studies are not in line with our findings.
Compared with the usual care, these studies report no significant
difference in prenatal hospitalizations [14] and mode of delivery
[10,11] in RM group. When looking at the neonatal outcomes,
some contradictions were found: the study of Corwin et al [9]
and Morrison et al [12] states that infants born to monitored
women were less likely to be admitted to a NIC compared with
women without a RM follow-up program, which are in line with
our findings. The Collaborative Home Uterine Monitoring Study
Group [15] and Homko et al [16] did not find any difference
between the two groups in neonatal hospitalization to the NIC.
A side note which has to make is that some of the mentioned
studies are dating back to 1995, which is in contradiction with
the rapid technological advancements that have been made in
the last decade.
Possible Explanations
A possible hypothesis of the differences in admission to the
prenatal observational ward, admission to the NIC and the
gestational outcomes is the hypothesis that preeclampsia is
possibly a result of gestational hypertension or essential
hypertension [18-20]. This may be due to the possibility to start
or adjust an antihypertensive drugs therapy to reduce a high
systolic or diastolic blood pressure which can be picked up by
RM. There are some studies which mentioned a reduced risk
of developing severe hypertension and preeclampsia associated
with the use of antihypertensive drugs [21-24]. However, these
results are in contradiction with the review of Duley [25], who
states that antihypertensive drugs may be effective at reducing
the risk of severe hypertension, but not of preeclampsia. Further
examination of the influence of antihypertension drugs therapy
on the development of severe hypertension or preeclampsia
when moderate hypertension is diagnosed, is necessary to obtain
clarification herein.
When women are diagnosed with preeclampsia, an induction
of labor is often necessary for the prevent of further
complications [26,27]. The explanation of more inductions in
CC could be the higher number of women diagnosed with
preeclampsia in this group. Gestational hypertension is not often
a requirement to induce women, and a spontaneous onset of
their labor is preferred. This can be the cause of the higher
number of spontaneous start of labor in RM.
Additionally, our study shows that there are no differences in
prenatal consults between RM and CC. These findings are in
contradiction with the statement that medicalization of childbirth
has gone too far, which arises from different angles [28-33].
Our study showed that adding RM devices to standard prenatal
care does not mean an increase of total amount of echo’s, CTG’s
or other prenatal consultations. In addition, RM opens the
perspective to timely initiative and monitor antihypertensive
treatments for gestational hypertension. As stated in the review
of Gyselaers et al [34], offering RM to a high risk group allows
timely identification of most cases of alarm events without
increasing ambulatory or in-hospital interventions. This also
opens perspectives to reverse the current evolution of antenatal
interventions leading to more interventions and as such to ever
increasing medicalized antenatal care.
Recommendations for Further Research
Although women in the RM group were invited for an extra
prenatal consult to evaluate fetal and maternal wellbeing when
events occurred, no statistical significant difference is present
in prenatal consultations (total number of consultations, total
number of CTG’s, and total number of echo’s) in the RM group
versus the CC group. This indicates that RM does not cause
extra prenatal consultations but, when further implemented, can
ensure a reduction in this number when obstetricians and
gynecologists are more familiar with this system. A study to
evaluate the cost-effectiveness of a RM follow-up program
needs to be performed later. Additionally, early detection of
GHD in the monitoring group demonstrated the value of
objective measurements of increase in blood pressure by a
remote blood pressure monitoring device. The patients not
receiving these devices relied on standard prenatal care, where
a GHD mostly will be discovered by chance or when the patient
comes to the hospital with self-reported complaints, for example,
headache or blurred vision. In these cases, the degree of the
GHD is often severe and an active management is necessary
[1]. Recent resources showed that providing information about
GHD enables women to spot signs and symptoms of these
diseases. This leads to earlier diagnoses and management, and
reduces morbidity and mortality rates [35]. It is possible that
combining patient education and a remote prenatal follow-up
program could make morbidity and mortality rates further
decrease, but this requires further research. Finally, more
research should be done to the influence of antihypertension
drugs therapy on the development of severe hypertension or
preeclampsia when moderate hypertension is diagnosed. When
the effect of the medication is clarified, the added value of RM
in the prenatal care of women diagnosed with GHD will be
more apparent.
Conclusions
Prenatal RM follow-up is linked with an increased prevalence
of a spontaneous start of the birth process, when compared with
CC. This may relate to a trend for less maternal and neonatal
hospitalizations in RM group compared with the CC group.
This study illustrates that RM opens perspectives to timely
initiate and monitor antihypertensive treatments for gestational
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hypertension, and early identifications of alarm events without
increasing ambulatory or in-hospital interventions. To our
knowledge, this is the first publication about a prenatal follow-up
program for pregnant women with GHD to date. Further
examinations about the effect of a prenatal RM follow-up
program for women at risk for the development of GHD needs
to be done in a randomized controlled trial to confirm these
results.
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